U.S. Food and Drug Administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma

1. De Claro, R.A.
2. McGinn, K.
3. Kwitkowski, V.
4. Bullock, J.
5. Khandelwal, A.
6. Habtemariam, B.
7. Ouyang, Y.
8. Saber, H.
9. Lee, K.
10. Koti, K.
11. Rothmann, M.
12. Shapiro, M.
13. Borrego, F.
14. Clouse, K.
15. Chen, X.H.
16. Brown, J.
17. Akinsanya, L.
18. Kane, R.
19. Kaminskas, E.
20. Farrell, A.
21. Pazdur, R.